Comparative Pharmacology
Head-to-head clinical analysis: ANTHIM versus RAXIBACUMAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTHIM versus RAXIBACUMAB.
ANTHIM vs RAXIBACUMAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Raxibacumab is a monoclonal antibody that binds to the protective antigen (PA) component of Bacillus anthracis toxins, preventing PA from binding to host cell receptors and thereby inhibiting the intracellular entry of lethal factor and edema factor. This neutralizes the lethal and edema toxins, reducing pathogenicity.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
Single intravenous dose of 40 mg/kg administered over 30 minutes.
None Documented
None Documented
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Terminal elimination half-life approximately 12-24 hours (mean ~18 hours) in patients with normal renal function; half-life extends in renal impairment.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Primarily renal excretion as intact protein; >90% of administered dose recovered in urine over 48 hours.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody